Navigation Links
Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections

Vancouver, BC, Canada (PRWEB) December 12, 2012

The MRSAid photodisinfection project, an innovative non-pharmaceutical pilot program conducted over the course of 12 months at Vancouver General Hospital (VGH), has proven successful in reducing surgical site infections (SSIs) by 39 per cent, according to results released by VGH. Under this innovative project, patients undergoing major surgeries at VGH, including cardiac, spinal, orthopedic, thoracic, vascular, breast reconstruction, and neurological surgeries, were treated with MRSAid nasal decolonization therapy prior to surgery. Photodisinfection therapy combined with chlorhexidine body wipes were shown to significantly decrease a patient’s load of Methicillin resistant staphylococcus aureus (MRSA) and Methicillin sensitive staphylococcus aureus (MSSA) on their skin and in their nasal cavity. The pilot is the first of its kind and has saved the Vancouver General Hospital an estimated $1.9 million in costs associated with treating patients who develop SSIs.

“By using these two therapies in conjunction, we were able to reduce SSI occurrences by 39 per cent over the study’s duration which marks impressive gains for patient quality and safety,” said Dr. Elizabeth Bryce, Regional Medical Director, Infection Control at Vancouver Coastal Health. “Most importantly, the decrease in SSIs translates into less morbidity for our patients.”

Patients that develop infections after surgery are five times more likely to be readmitted to a hospital, and twice as likely to die. On average, SSIs require an extended hospital stay of eight days in an acute care setting, and adds hundreds of millions of dollars in additional costs to the Canadian healthcare system every year. The MRSAid photodisinfection pilot which treated more than 5000 patients saw a decrease in SSIs from 4 to 1.25 cases per month, resulting in the freeing of 533 patient beds and an addition of 138 surgeries performed. During the course of the study actual occurrences of SSIs dropped from 85 to 50 cases.

“The results of this project mark a global first for photodisinfection as a non-antibiotic approach to significant reductions in surgical site infections, one of the leading sources of healthcare associated infections,” said Carolyn Cross, Chairman and CEO of Ondine Biomedical Inc., the global leader of photodisinfection technologies. “As a partner in this initiative, we want to thank the dedicated team members at VGH for their pioneering work in the field of non-antibiotic infection control and patient safety, and for their willingness to champion innovation and change.”

Preliminary results on MRSAid nasal decolonization have been presented at two infectious disease conferences. Dr. Titus Wong and his team at Vancouver General Hospital (VGH) won the John Conly Innovation Academy Award at the AMMI - CACMID Annual Conference for their implementation of a universal nasal decolonization program.

“We are proud to be the first hospital in Canada and in North America to implement a program using this combined approach of innovative light-activated technology that will prevent patients from contracting infections post-surgery,” said Dr. Titus Wong, Medical Microbiologist, Vancouver General Hospital. “Not only will this new approach prevent infections and reduce costs, but it will also allow us to reinvest that saved money into direct patient care.”

About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: and For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

About Vancouver Coastal Health
Vancouver Coastal Health provides a full range of health care services, ranging from hospital treatment to community-based residential, home health, mental health and public health services. VCH is responsible for the delivery of $3 billion in care to residents of Vancouver, North Vancouver, West Vancouver, Richmond, and in the coastal mountain communities.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
2. SPIE Urges Congress, President to Avoid Fiscal Cliff and Support Science and Technology to Strengthen Economy
3. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
4. A Sewage Treatment Plant Goes Underground Using In-Pipe Technology Company, Inc. Bioaugmentation
5. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
6. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
7. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
8. Global Agricultural Biotechnology Industry
9. Fast forward to the past: NASA technologists test game-changing data-processing technology
10. Researchers improve technology to detect hazardous chemicals
11. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/18/2015)... 2015 --> ... market report titled  Gesture Recognition Market - Global Industry ... 2021. According to the report, the global gesture recognition market was valued ... reach US$29.1 bn by 2021, at a CAGR of ... America dominated the global gesture recognition market ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):